Julie Deane Saba MD

Grant Support

• Characterizing the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS): a fundamental step in the development of a targeted cure for this novel atypical sphingolipidosisUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2029
• Characterizing the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS): a fundamental step in the development of a targeted cure for this novel atypical sphingolipidosisUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2029
• Characterizing the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS): a fundamental step in the development of a targeted cure for this novel atypical sphingolipidosisUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2029
• Characterizing the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS): a fundamental step in the development of a targeted cure for this novel atypical sphingolipidosisUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2029
• Characterizing the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS): a fundamental step in the development of a targeted cure for this novel atypical sphingolipidosisUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2029
• Proof-of-concept for the use of enzyme replacement therapy as a lifesaving treatment for sphingosine phosphate lyase insufficiency syndromeUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2026
• Proof-of-concept for the use of enzyme replacement therapy as a lifesaving treatment for sphingosine phosphate lyase insufficiency syndromeUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2026
• Adeno-associated virus-mediated SGPL1 gene therapy as a first-in-class treatment for idiopathic pulmonary fibrosis that acts by reducing sphingosine-1-phosphate and downstream profibrotic signalingUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2026
• Adeno-associated virus-mediated SGPL1 gene therapy as a first-in-class treatment for idiopathic pulmonary fibrosis that acts by reducing sphingosine-1-phosphate and downstream profibrotic signalingUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2026
• Proof-of-concept for the use of enzyme replacement therapy as a lifesaving treatment for sphingosine phosphate lyase insufficiency syndromeUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2026
• Adeno-associated virus-mediated SGPL1 gene therapy as a first-in-class treatment for idiopathic pulmonary fibrosis that acts by reducing sphingosine-1-phosphate and downstream profibrotic signalingUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2026
• Adeno-associated virus-mediated SGPL1 gene therapy as a first-in-class treatment for idiopathic pulmonary fibrosis that acts by reducing sphingosine-1-phosphate and downstream profibrotic signalingUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2026
• Adeno-associated virus-mediated SGPL1 gene therapy as a first-in-class treatment for idiopathic pulmonary fibrosis that acts by reducing sphingosine-1-phosphate and downstream profibrotic signalingUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2026
• Adeno-associated virus-mediated SGPL1 gene therapy as a first-in-class treatment for idiopathic pulmonary fibrosis that acts by reducing sphingosine-1-phosphate and downstream profibrotic signalingUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2026
• Proof-of-concept for the use of enzyme replacement therapy as a lifesaving treatment for sphingosine phosphate lyase insufficiency syndromeUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2026
• Adeno-associated virus-mediated SGPL1 gene therapy as a first-in-class treatment for idiopathic pulmonary fibrosis that acts by reducing sphingosine-1-phosphate and downstream profibrotic signalingUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2026
• Adeno-associated virus-mediated SGPL1 gene therapy as a first-in-class treatment for idiopathic pulmonary fibrosis that acts by reducing sphingosine-1-phosphate and downstream profibrotic signalingUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2026
• Adeno-associated virus-mediated SGPL1 gene therapy as a first-in-class treatment for idiopathic pulmonary fibrosis that acts by reducing sphingosine-1-phosphate and downstream profibrotic signalingUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2026
• Validating absolute lymphocyte count and plasma sphingosine-1-phosphate as disease biomarkers of sphingosine phosphate lyase insufficiency syndrome in anticipation of a pyridoxine clinical trialUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2022–2025